SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the Quarterly Period Ended March 31, 1996
Or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from to
Commission file number 0-14217
ML VENTURE PARTNERS II, L.P.
================================================================================
(Exact name of registrant as specified in its charter)
Delaware 13-3324232
================================================================================
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
World Financial Center, North Tower
New York, New York 10281-1326
================================================================================
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 449-1000
Not applicable
================================================================================
Former name, former address and former fiscal year, if changed since last report
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
<PAGE>
ML VENTURE PARTNERS II, L.P.
INDEX
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
Balance Sheets as of March 31, 1996 (Unaudited) and December 31, 1995
Schedule of Portfolio Investments as of March 31, 1996 (Unaudited)
Statements of Operations for the Three Months Ended March 31, 1996 and 1995
(Unaudited)
Statements of Cash Flows for the Three Months Ended March 31, 1996 and 1995
(Unaudited)
Statement of Changes in Partners' Capital for the Three Months Ended March 31,
1996 (Unaudited)
Notes to Financial Statements (Unaudited)
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
Item 2. Changes in Securities.
Item 3. Defaults upon Senior Securities.
Item 4. Submission of Matters to a Vote of Security Holders.
Item 5. Other Information.
Item 6. Exhibits and Reports on Form 8-K.
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
ML VENTURE PARTNERS II, L.P.
BALANCE SHEETS
<TABLE>
March 31, 1996 December 31,
(Unaudited) 1995
ASSETS
Investments - Notes 2, 9, 10 and 11
Portfolio investments, at fair value
(cost $33,675,294 at March 31, 1996
<S> <C> <C> <C> <C> <C>
and $38,000,476 at December 31, 1995) $ 53,489,300 $ 73,125,660
Short-term investments, at amortized cost 34,905,720 17,369,428
Cash and cash equivalents 69,058 685,917
Accrued interest receivable 950,051 870,177
Deposit in escrow - 184,502
Receivable from securities sold 3,838,349 2,809,725
---------------- -----------------
TOTAL ASSETS $ 93,252,478 $ 95,045,409
================ =================
LIABILITIES AND PARTNERS' CAPITAL
Liabilities:
Cash distribution payable - Note 7 $ 21,378,498 $ 14,336,506
Accounts payable 183,753 118,288
Due to Management Company - Note 4 205,188 224,683
Due to Independent General Partners - Note 5 28,500 23,400
---------------- -----------------
Total liabilities 21,795,939 14,702,877
---------------- -----------------
Partners' Capital:
Managing General Partner 3,910,449 1,471,685
Individual General Partners 1,591 1,457
Limited Partners (120,000 Units) 47,730,493 43,744,206
Unallocated net unrealized appreciation of investments - Note 2 19,814,006 35,125,184
---------------- -----------------
Total partners' capital 71,456,539 80,342,532
---------------- -----------------
TOTAL LIABILITIES AND PARTNERS' CAPITAL $ 93,252,478 $ 95,045,409
================ =================
</TABLE>
See notes to financial statements.
<PAGE>
ML VENTURE PARTNERS II, L.P.
SCHEDULE OF PORTFOLIO INVESTMENTS (UNAUDITED)
March 31, 1996
Active Portfolio Investments:
<TABLE>
Initial Investment
Company / Position Date Cost Fair Value
Biocircuits Corporation*(A)
<C> <C> <C> <C>
128,817 shares of Common Stock May 1991 $ 1,422,501 $ 434,757
2,000,000 shares of Preferred Stock 1,000,000 1,687,500
Warrants to purchase 594,000 shares of Preferred Stock at
$.60 per share, expiring on 12/18/96 0 144,788
- -------------------------------------------------------------------------------------------------------------------------------
Borg-Warner Automotive, Inc.*(A)
444,664 shares of Common Stock Sept. 1988 2,223,320 11,088,809
- -------------------------------------------------------------------------------------------------------------------------------
Borg-Warner Security Corporation*(A)
500,000 shares of Common Stock Sept. 1988 2,500,000 4,171,875
- -------------------------------------------------------------------------------------------------------------------------------
Clarus Medical Systems, Inc.*
179,028 shares of Preferred Stock Jan. 1991 2,389,168 895,152
Warrants to purchase 4,048 shares of Common Stock
at $18.75 per share, expiring on 7/31/97 0 0
Warrants to purchase 14,043 shares of Common Stock
at $.05 per share, expiring between 3/7/00 and 7/3/00 0 0
Warrants to purchase 2,826 shares of Preferred Stock
at $5.00 per share, expiring on 3/7/00 0 0
- -------------------------------------------------------------------------------------------------------------------------------
Corporate Express, Inc.(A)(B)
239,503 shares of Common Stock May 1992 124,456 6,322,879
- -------------------------------------------------------------------------------------------------------------------------------
Diatide, Inc.*(C)
1,349,508 shares of Preferred Stock Dec. 1991 2,986,023 4,454,528
- -------------------------------------------------------------------------------------------------------------------------------
Elantec, Inc.(A)(B)
243,245 shares of Common Stock Aug. 1988 886,574 1,313,523
- -------------------------------------------------------------------------------------------------------------------------------
Horizon Cellular Telephone Company, L.P.:
HCTC Investment, L.P.
10% Promissory Note due 3/26/98 May 1992 2,587,500 2,587,500
SPTHOR Corporation
10% Promissory Note due 3/26/98 May 1992 646,875 646,875
34.5 shares of Common Stock 215,625 215,625
- -------------------------------------------------------------------------------------------------------------------------------
I.D.E. Corporation
493,391 shares of Preferred Stock Mar. 1988 1,110,909 0
- -------------------------------------------------------------------------------------------------------------------------------
IDEC Pharmaceuticals Corporation(A):
ML/MS Associates, L.P.*
34.4% Limited Partnership interest June 1989 3,960,000 6,219,785
MLMS Cancer Research, Inc.*(D)
400,000 shares of Common Stock July 1989 69,566 62,822
- -------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
ML VENTURE PARTNERS II, L.P.
SCHEDULE OF PORTFOLIO INVESTMENTS (UNAUDITED) - continued
March 31, 1996
<TABLE>
Initial Investment
Company / Position Date Cost Fair Value
Inference Corporation(A)(B)
<C> <C> <C> <C>
109,424 shares of Common Stock Apr. 1993 $ 580,889 $ 1,518,258
Brightware, Inc.
140,485 shares of Common Stock Apr. 1993 39,252 100,000
Warrants to purchase 38,737 shares of Common Stock
at $.40 per share, expiring on 4/19/99 1,138 0
Warrants to purchase 4,846 shares of Common Stock
at $.40 per share, expiring on 12/16/97 327 0
Warrants to purchase 59,166 shares of Common Stock
at $.80 per share, expiring on 6/10/98 3,986 0
- -------------------------------------------------------------------------------------------------------------------------------
Ligand Pharmaceuticals Inc.(A)(B)
2,417 shares of Common Stock Apr. 1989 10,719 14,049
Warrants to purchase 3,167 shares of Common Stock at
$7.22 per share to $9.60 per share, expiring between
5/31/97 and 7/31/97 0 0
- -------------------------------------------------------------------------------------------------------------------------------
Neocrin Company*(B)(E)
484,300 shares of Preferred Stock June 1991 4,203,716 193,720
Warrants to purchase 922,050 shares of Preferred Stock
at $.40 per share, expiring on 1/3/01 92 0
- -------------------------------------------------------------------------------------------------------------------------------
OccuSystems, Inc.(A)(B)
227,864 shares of Common Stock June 1993 1,139,320 3,887,930
- -------------------------------------------------------------------------------------------------------------------------------
Photon Dynamics, Inc.*(A)
425,235 shares of Common Stock Sept. 1988 2,452,226 1,929,504
Warrants to purchase 6,062 shares of Common Stock
at $5.40 per share, expiring on 6/30/00 0 0
- -------------------------------------------------------------------------------------------------------------------------------
Raytel Medical Corporation*(A)(B)
350,000 shares of Common Stock Feb. 1990 1,334,469 1,843,311
Options to purchase 27,969 shares of Common Stock
at $1.42 per share, expiring on 10/31/01 0 114,114
- -------------------------------------------------------------------------------------------------------------------------------
Sanderling Biomedical, L.P.*
80% Limited Partnership interest May 1988 1,786,643 3,641,996
- -------------------------------------------------------------------------------------------------------------------------------
Totals from Active Portfolio Investments $ 33,675,294 $ 53,489,300
---------------------------------
</TABLE>
<PAGE>
ML VENTURE PARTNERS II, L.P.
SCHEDULE OF PORTFOLIO INVESTMENTS (UNAUDITED) - continued
March 31, 1996
Supplemental Information: Liquidated Portfolio Investments(F)
<TABLE>
Cost Realized Gain Return
<S> <C> <C> <C>
Totals from Liquidated Portfolio Investments $ 82,383,446 $ 78,785,408 $ 161,168,854
=========================================================
Combined Net Combined
Unrealized and Fair Value
Cost Realized Gain and Return
Totals from Active & Liquidated Portfolio Investments $ 116,058,740 $ 98,599,414 $ 214,658,154
=========================================================
</TABLE>
(A) Public company
(B) During and/or subsequent to the end of the quarter, the Partnership
liquidated equity securities of such investment. See Notes 9 and 11 of
Notes to Financial Statements for summarized information.
(C) During the quarter ended March 31, 1996, Diatech, Inc. changed its name to
Diatide, Inc.
(D) In January 1996, the Partnership paid $22,609 to MLMS Cancer Research, Inc.
in connection with a call on the non-interest bearing promissory note
payable on demand to MLMS. The payment increased the cost basis of the
Partnership's common stock investment in the company from $46,957 to
$69,566 and reduced the outstanding obligation under the promissory note
from $393,043 to $370,434.
(E) In January 1996, the Partnership's warrant to purchase 13,005 shares of
Neocrin Company common stock at $5 per share expired unexercised.
Additionally, in January 1996, the Partnership purchased 36,882 shares of
preferred stock of Neocrin Company and a warrant to purchase 922,050 shares
of Neocrin preferred stock at $.40 per share for $184,502.
(F) Amounts provided for "Supplemental Information: Liquidated Portfolio
Investments" are cumulative from inception through March 31, 1996.
* May be deemed an affiliated person of the Partnership as defined in the
Investment Company Act of 1940.
See notes to financial statements.
<PAGE>
ML VENTURE PARTNERS II, L.P.
STATEMENTS OF OPERATIONS (UNAUDITED)
For the Three Months Ended March 31,
<TABLE>
1996 1995
---------------- ---------
INVESTMENT INCOME AND EXPENSES
<S> <C> <C>
Interest from short-term investments $ 210,732 $ 175,029
Interest and other income from portfolio investments 81,309 127,069
Dividend income from portfolio investments 66,700 66,700
---------------- ---------------
Total investment income 358,741 368,798
---------------- ---------------
Expenses:
Management fee - Note 4 205,188 322,618
Professional fees 33,071 89,901
Mailing and printing 108,126 157,477
Independent General Partners' fees - Note 5 29,256 27,183
Custodial fees 3,618 3,428
Miscellaneous 650 585
---------------- ---------------
Total expenses 379,909 601,192
---------------- ---------------
NET INVESTMENT LOSS (21,168) (232,394)
Net realized gain from portfolio investments 27,824,851 7,945,512
---------------- ---------------
NET REALIZED GAIN FROM OPERATIONS
(allocable to Partners) - Note 3 27,803,683 7,713,118
Net change in unrealized appreciation of investments (15,311,178) 3,775,345
---------------- ---------------
NET INCREASE IN NET ASSETS RESULTING FROM
OPERATIONS $ 12,492,505 $ 11,488,463
================ ===============
</TABLE>
See notes to financial statements.
<PAGE>
ML VENTURE PARTNERS II, L.P.
STATEMENTS OF CASH FLOWS (UNAUDITED)
For the Three Months Ended March 31,
<TABLE>
1996 1995
---------------- ---------
CASH FLOWS PROVIDED FROM (USED FOR)
OPERATING ACTIVITIES
<S> <C> <C>
Net investment loss $ (21,168) $ (232,394)
Adjustments to reconcile net investment loss to cash provided from (used for)
operating activities:
(Increase) decrease in accrued interest receivable (79,874) 185,352
Increase in accrued interest on short-term investments (108,180) (21,208)
Increase in payables, net 51,070 164,135
---------------- ---------------
Cash provided from (used for) operating activities (158,152) 95,885
---------------- ---------------
CASH FLOWS PROVIDED FROM (USED FOR)
INVESTING ACTIVITIES
Net purchase of short-term investments (17,428,112) (11,195,820)
Cost of portfolio investments purchased (207,111) (658,093)
Net proceeds from the sale of portfolio investments 31,328,520 9,831,338
Deposit released from escrow 184,502 -
Repayment of investments in notes - 2,019,721
---------------- ---------------
Cash provided from (used for) investing activities 13,877,799 (2,854)
---------------- ---------------
CASH FLOWS FOR FINANCING ACTIVITIES
Cash distribution to Partners (14,336,506) -
---------------- ---------------
Increase (decrease) in cash and cash equivalents (616,859) 93,031
Cash and cash equivalents at beginning of period 685,917 638,868
---------------- ---------------
CASH AND CASH EQUIVALENTS AT END
OF PERIOD $ 69,058 $ 731,899
================ ===============
</TABLE>
See notes to financial statements.
<PAGE>
ML VENTURE PARTNERS II, L.P.
STATEMENT OF CHANGES IN PARTNERS' CAPITAL (UNAUDITED)
For the Three Months Ended March 31, 1996
<TABLE>
Unallocated
Managing Individual Net Unrealized
General General Limited Appreciation of
Partner Partners Partners Investments Total
<S> <C> <C> <C> <C> <C>
Balance at beginning of period $ 1,471,685 $ 1,457 $ 43,744,206 $ 35,125,184 $ 80,342,532
Accrued cash distribution,
paid April 26, 1996 - Note 7 (3,377,898) (600) (18,000,000) - (21,378,498)
Net investment loss 29,094 (2) (50,260) - (21,168)
Net realized gain from portfolio
investments 5,787,568 736 22,036,547 - 27,824,851
Net change in unrealized
appreciation of investments - - - (15,311,178) (15,311,178)
------------- -------- -------------- -------------- ----------------
Balance at end of period $ 3,910,449 $ 1,591 $ 47,730,493(A) $ 19,814,006 $ 71,456,539
============= ======== ============== ============== ================
</TABLE>
(A) The net asset value per unit of limited partnership interest, including an
assumed allocation of net unrealized appreciation of investments, was $529
at March 31, 1996. Cumulative cash distributions paid or accrued to Limited
Partners from inception to March 31, 1996 totaled $1,040 per Unit.
See notes to financial statements.
<PAGE>
ML VENTURE PARTNERS II, L.P.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
1. Organization and Purpose
ML Venture Partners II, L.P. (the "Partnership") is a Delaware limited
partnership formed on February 4, 1986. MLVPII Co., L.P., the managing general
partner of the Partnership (the "Managing General Partner") and four individuals
(the "Individual General Partners") are the general partners of the Partnership.
The general partner of MLVPII Co., L.P. is Merrill Lynch Venture Capital Inc.
(the "Management Company"), an indirect subsidiary of Merrill Lynch & Co., Inc.
DLJ Capital Management Corporation (the "Sub-Manager"), an indirect subsidiary
of Donaldson, Lufkin & Jenrette, Inc., is the sub-manager of the Partnership,
pursuant to a sub-management agreement among the Partnership, the Management
Company, the Managing General Partner and the Sub-Manager.
The Partnership's objective is to achieve long-term capital appreciation from
its portfolio of venture capital investments in new and developing companies and
other special investment situations. The Partnership does not engage in any
other business or activity. The Partnership is scheduled to terminate on
December 31, 1997. However, pursuant to the Partnership Agreement, the
Individual General Partners can extend the termination date for up to two
additional two-year periods if they determine that such extensions would be in
the best interest of the Partnership.
2. Significant Accounting Policies
Valuation of Investments - Short-term investments are carried at amortized cost
which approximates market. Portfolio investments are carried at fair value as
determined quarterly by the Sub-Manager under the supervision of the Individual
General Partners and the Managing General Partner. The fair value of
publicly-held portfolio securities is adjusted to the closing public market
price for the last trading day of the accounting period discounted by a factor
of 0% to 50% for sales restrictions. Factors considered in the determination of
an appropriate discount include, underwriter lock-up or Rule 144 trading
restrictions, insider status where the Partnership either has a representative
serving on the company's Board of Directors or is greater than a 10%
shareholder, and other liquidity factors such as the size of the Partnership's
position in a given company compared to the trading history of the public
security. Privately-held portfolio securities are carried at cost until
significant developments affecting the portfolio company provide a basis for
change in valuation. The fair value of private securities is adjusted 1) to
reflect meaningful third-party transactions in the private market or 2) to
reflect significant progress or slippage in the development of the company's
business such that cost is no longer reflective of fair value. As a venture
capital investment fund, the Partnership's portfolio investments involve a high
degree of business and financial risk that can result in substantial losses. The
Sub-Manager considers such risks in determining the fair value of the
Partnership's portfolio investments.
<PAGE>
ML VENTURE PARTNERS II, L.P.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
Use of Estimates - The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates. Investment
Transactions - Investment transactions are recorded on the accrual method.
Portfolio investments are recorded on the trade date, the date the Partnership
obtains an enforceable right to demand the securities or payment therefor.
Realized gains and losses on investments sold are computed on a specific
identification basis. Income Taxes - No provision for income taxes has been made
since all income and losses are allocable to the Partners for inclusion in their
respective tax returns. The Partnership's net assets for financial reporting
purposes differ from its net assets for tax purposes. Net unrealized
appreciation of investments of $19.8 million at March 31, 1996, which was
recorded for financial statement purposes, was not recognized for tax purposes.
Additionally, from inception to March 31, 1996, timing differences primarily
relating to realized losses totaling $1.2 million have been deducted on the
Partnership's financial statements and syndication costs relating to the selling
of Units totaling $11.3 million were charged to partners' capital on the
financial statements. These amounts have not been deducted or charged against
partners' capital for tax purposes. Statements of Cash Flows - The Partnership
considers its interest-bearing cash account to be cash equivalents.
3. Allocation of Partnership Profits and Losses
The Partnership Agreement provides that the Managing General Partner will be
allocated, on a cumulative basis over the life of the Partnership, 20% of the
Partnership's aggregate investment income and net realized gains and losses from
venture capital investments, provided that such amount is positive. All other
gains and losses of the Partnership are allocated among all the Partners
(including the Managing General Partner) in proportion to their respective
capital contributions to the Partnership. From its inception to March 31, 1996,
the Partnership had a $82.6 million net gain from its venture capital
investments, which includes interest and other income from portfolio investments
totaling $3.8 million.
4. Related Party Transactions
The Management Company is responsible for the management and administrative
services necessary for the operation of the Partnership and receives a
management fee at the annual rate of 2.5% of the gross capital contributions to
the Partnership, reduced by selling commissions, organizational and offering
expenses paid by the Partnership, capital distributed and realized capital
losses with a minimum annual fee of $200,000. Such fee is determined and payable
quarterly.
<PAGE>
ML VENTURE PARTNERS II, L.P.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
5. Independent General Partners' Fees
As compensation for services rendered to the Partnership, each of the three
Independent General Partners receives $20,000 annually in quarterly
installments, $1,400 for each meeting of the General Partners attended or for
each other meeting, conference or engagement in connection with Partnership
activities at which attendance by an Independent General Partner is required and
$1,200 for each audit committee meeting attended ($500 if an audit committee
meeting is held on the same day as a meeting of the Independent General
Partners).
6. Commitments
The Partnership has an outstanding commitment of $370,434 payable on demand,
when and if called for by MLMS Cancer Research, Inc. The Partnership has a 34.8%
ownership interest in MLMS Cancer Research which is the general partner of ML/MS
Associates, L.P., formerly a research and development joint venture with IDEC
Pharmaceuticals Corporation. The Partnership also owns a 34.4% limited
partnership interest in ML/MS Associates.
7. Cash Distributions
On February 29, 1996, the General Partners approved a cash distribution to
Partners totaling $21,378,498; $18,000,000, or $150 per Unit, to the Limited
Partners and $3,378,498 to the General Partners. The distribution was paid on
April 26, 1996 to Limited Partners of record on March 31, 1996.
Cash distributions paid or accrued during the periods presented and cumulative
cash distributions to Partners from inception of the Partnership through March
31, 1996 are listed below:
<TABLE>
General Limited Per $1,000
Distribution Date Partners Partners Unit
- ------------------------------------------------ --------------- ---------------- ---------
<S> <C> <C> <C> <C> <C>
Inception to December 31, 1994 $ 1,400,000 $ 58,800,000 $ 490
April 11, 1995 2,234,189 9,000,000 75
October 5, 1995 5,001,136 27,000,000 225
January 12, 1996 2,336,506 12,000,000 100
April 26, 1996 (accrued at March 31, 1996) 3,378,498 18,000,000 150
--------------- ---------------- ---------
Cumulative totals at March 31, 1996 $ 14,350,329 $ 124,800,000 $ 1,040
=============== ================ =========
</TABLE>
Additionally, on May 8, 1996, the General Partners approved a cash distribution
to Partners totaling $23,439,491; $19.2 million, or $160 per Unit, to the
Limited Partners and $4,239,491 to the General Partners. The distribution will
be paid in July 1996 to Limited Partners of record on June 30, 1996 and will
bring cumulative cash distributions paid to Limited Partners to $144 million, or
$1,200 per $1,000 Unit. Cumulative cash distributions paid to the General
Partners will total $18.6 million.
<PAGE>
ML VENTURE PARTNERS II, L.P.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
8. Pending Litigation
The Partnership has been named as a defendant, along with other entities and
individuals, in an action involving In-Store Advertising, Inc. ("ISA"). The
action is a purported class action suit wherein the plaintiffs, who purchased
shares of ISA in its July 19, 1990 initial public offering through November 8,
1990, allege violations under certain sections of the Securities Act of 1933,
the Securities Exchange Act of 1934 and common law. The plaintiffs seek
rescission of their purchases of ISA common stock together with damages and
certain costs and expenses. The Partnership believes it has meritorious defenses
to the allegations in the Amended Complaint and that the cost of resolution of
the litigation will not have a material impact on the financial condition of the
Partnership. As of March 31, 1996, the Partnership has incurred cumulative legal
expenses totaling $236,000 related to the litigation.
9. Portfolio Investments
During the three months ended March 31, 1996, the Partnership liquidated equity
securities of the following portfolio companies:
<TABLE>
Number of Realized
Company Shares/Warrants Cost Gain (Loss) Return
<S> <C> <C> <C> <C>
CellPro, Incorporated 50,166 $ 93,241 $ 744,215 $ 837,456
Corporate Express, Inc. 320,000 940,025 8,827,460 9,767,485
Inference Corporation 80,000 223,801 1,336,816 1,560,617
Ligand Pharmaceuticals, Inc. 217,358 528,967 1,979,901 2,508,868
Neocrin Company 13,005 130 (130) 0
OccuSystems, Inc. 176,000 880,000 2,766,218 3,646,218
Raytel Medical Corporation 345,753 714,834 2,449,363 3,164,197
SDL, Inc. 379,155 999,015 9,120,519 10,119,534
Viasoft, Inc. 47,795 152,280 600,489 752,769
--------------- ---------------- ----------------
Totals $ 4,532,293 $ 27,824,851 $ 32,357,144
=============== ================ ================
</TABLE>
<PAGE>
ML VENTURE PARTNERS II, L.P.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
10. Classification of Portfolio Investments
As of March 31, 1996, the Partnership's investments in portfolio companies were
categorized as follows:
<TABLE>
% of
Type of Investments Cost Fair Value Net Assets*
- ------------------- ---------------- --------------- -----------
<S> <C> <C> <C>
Common Stock $ 13,004,368 $ 33,017,456 46.21%
Limited Partnerships 5,746,643 9,861,781 13.80%
Preferred Stock 11,689,908 7,375,688 10.32%
Debt Securities 3,234,375 3,234,375 4.53%
---------------- --------------- ----------
Total $ 33,675,294 $ 53,489,300 74.86%
================ =============== ==========
Country/Geographic Region
Midwestern U.S. $ 8,376,264 $ 26,366,645 36.90%
Western U.S. 17,752,098 19,218,127 26.89%
Eastern U.S. 7,546,932 7,904,528 11.07%
---------------- --------------- ----------
Total $ 33,675,294 $ 53,489,300 74.86%
================ =============== ==========
Industry
Business Services $ 3,763,776 $ 14,382,684 20.13%
Biotechnology 8,812,951 14,393,180 20.14%
Automotive Parts 2,223,320 11,088,809 15.52%
Semiconductors/Electronics 3,338,800 3,243,027 4.54%
Medical Devices and Services 10,349,946 5,313,342 7.44%
Telecommunications 3,450,000 3,450,000 4.83%
Computer Hardware/Software 1,736,501 1,618,258 2.26%
---------------- --------------- ----------
Total $ 33,675,294 $ 53,489,300 74.86%
================ =============== ==========
</TABLE>
* Percentage of net assets is based on fair value.
<PAGE>
ML VENTURE PARTNERS II, L.P.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
11. Subsequent Events
From April 1, 1996 to May 3, 1996, the Partnership sold the following
publicly-traded securities:
<TABLE>
Company Shares/Warrants Cost Realized Gain Return
<S> <C> <C> <C> <C>
Elantec Inc. 220,000 $ 826,137 $ 1,745,113 $ 2,571,250
Inference Corporation 20,000 106,172 268,828 375,000
Ligand Pharmaceuticals, Inc. 5,584 10,719 21,255 31,974
OccuSystems, Inc. 221,864 1,109,320 4,798,166 5,907,486
--------------- ---------------- ----------------
Totals $ 2,052,348 $ 6,833,362 $ 8,885,710
=============== ================ ================
</TABLE>
12. Interim Financial Statements
In the opinion of MLVPII Co., L.P., the managing general partner of the
Partnership, the unaudited financial statements as of March 31, 1996, and for
the three month period then ended, reflect all adjustments necessary for the
fair presentation of the results of the interim period.
<PAGE>
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.
Liquidity and Capital Resources
In January 1996, the Partnership made a $14.3 million cash distribution to
Partners. For the three months ended March 31, 1996, the Partnership received
proceeds from the sale of certain portfolio investments totaling $31.3 million.
As a result, as of March 31, 1996, the Partnership held $35 million in cash and
short-term investments; $34.9 million in short-term securities with maturities
of less than one year and $69,000 in an interest-bearing cash account. Interest
earned from such investments totaled $211,000 for the three months ended March
31, 1996. Interest earned in future periods is subject to fluctuations in
short-term interest rates and changes in amounts available for investment in
such securities.
In February 1996, the General Partners approved a cash distribution to Partners
totaling $21.4 million. Such distribution was paid in April 1996 to Partners of
record as of March 31, 1996.
Subsequent to the end of the quarter, from April 1, 1996 through May 3, 1996,
the Partnership realized $8.9 million from additional portfolio security sales.
As a result, the General Partners approved an additional cash distribution to
Partners totaling $23.4 million. Such distribution will be paid in July 1996 to
Limited Partners of record on June 30, 1996. Cumulative cash distributions paid
to Partners, after the distribution to be paid in July 1996, will total $162.6
million; $144 million to the Limited Partners, or $1,200 per $1,000 Unit, and
$18.6 million to the General Partners.
Generally, proceeds received from the sale of portfolio investments, after an
adequate reserve for operating expenses and follow-on investments in existing
portfolio companies, is distributed to Partners as soon as practicable after
receipt. Funds needed to cover future operating expenses and follow-on
investments will be obtained from the Partnership's existing cash reserves, from
interest and other investment income and from proceeds received from the sale of
portfolio investments.
During the three months ended March 31, 1996, the Partnership made follow-on
investments in two existing portfolio companies totaling $207,000. From its
inception to March 31, 1996, the Partnership had invested $116.1 million in 58
portfolio companies. The Partnership will not make investments in new portfolio
companies, however, it may make additional follow-on investments in certain
existing portfolio companies.
Results of Operations
For the three months ended March 31, 1996 and 1995, the Partnership had a net
realized gain from operations of $27.8 million and $7.7 million, respectively.
Net realized gain or loss from operations is comprised of 1) net realized gain
or loss from portfolio investments and 2) net investment income or loss
(interest and dividend income less operating expenses).
Realized Gains and Losses from Portfolio Investments - For the three months
ended March 31, 1996, the Partnership had a $27.8 million net realized gain from
portfolio investments. During the quarter, the Partnership sold shares of common
stock of eight of its publicly-traded portfolio companies for $32.4 million,
realizing a gain of $27.8 million. See Note 9 of Notes to Financial Statements
for a summary of sales by investment.
For the three months ended March 31, 1995, the Partnership had a $7.9 million
net realized gain from portfolio investments. During the quarter, the
Partnership sold shares of common stock of five of its publicly-traded portfolio
companies for $12.6 million, realizing a gain of $8.1 million. The number of
shares sold of each portfolio company were: 115,267 shares of Children's
Discovery Centers of America, Inc., 104,435 shares of Corporate Express, Inc.,
144,486 shares of Komag, Incorporated, 520,000 shares of Regeneron
Pharmaceuticals, Inc. and 60,000 shares of Viasoft, Inc. Additionally,
subsequent to the end of the quarter, the Partnership sold its investment in
TargetVision, Inc. for $250,000, resulting in the write-off $145,000 of its
$395,000 remaining investment in the company.
Investment Income and Expenses - For the three months ended March 31, 1996 and
1995, the Partnership had a net investment loss of $21,000 and $232,000,
respectively. The decrease in net investment loss for the 1996 period compared
to the same period in 1995, primarily was attributable to a decrease in the
management fee, as discussed below, and reduced professional fees and mailing
and printing expenses for the 1996 period. The decrease in professional fees for
the 1996 period compared to the 1995 period included a decline in legal and
accounting fees. The decline in mailing and printing expenses for the 1996
period compared to the 1995 period was due to a reduction in mailing and
printing costs associated with the Partnership's annual meeting.
Additionally, a decrease in interest and other income from portfolio investments
for the 1996 period compared to the 1995 period was mostly offset by an increase
in interest earned from short-term investments over the same periods. The
decrease in interest earned from portfolio investments for 1996 primarily was
due to the maturity of the Partnership's $2 million note due from SDL, Inc. in
March 1995. The increase in interest earned from short-term investments for 1996
was due to an increase in interest rates for the 1996 period and an increase in
funds available for investment in short-term securities, resulting from the
$31.3 million of proceeds from the sale of portfolio investments received during
the 1996 period as compared to $9.8 million received from portfolio liquidations
for the same period in 1995. Such proceeds are invested in short-term securities
until cash distributions are paid to Partners.
The Management Company is responsible for the management and administrative
services necessary for the operation of the Partnership. The Management Company
receives a management fee at an annual rate of 2.5% of the gross capital
contributions to the Partnership, reduced by selling commissions, organizational
and offering expenses paid by the Partnership, return of capital and realized
capital losses, with a minimum annual fee of $200,000. Such fee is determined
and payable quarterly. The management fee for the three months ended March 31,
1996 and 1995, was $205,000 and $323,000, respectively. The decline in the
management fee for the 1996 period compared to the same period in 1995 is due to
the portfolio liquidations and subsequent distributions made to Partners since
March 31, 1995. The management fee will continue to decline in future periods as
the Partnership's investment portfolio continues to mature and cash
distributions are paid to Partners. The management fee and other operating
expenses are paid with funds provided from operations. Funds provided from
operations for the period were obtained from interest earned from short-term
investments, interest and other income from portfolio investments and proceeds
from the sale of certain portfolio investments.
Unrealized Gains and Losses and Changes in Unrealized Appreciation or
Depreciation of Portfolio Investments - For the three months ended March 31,
1996, the Partnership had a $2.7 million net unrealized gain from its portfolio
investments, primarily resulting from the net upward revaluation of its
remaining publicly traded securities. Additionally, during the three month
period, $18 million was transferred from unrealized gain to realized gain
related to the portfolio investments sold during the quarter, as discussed
above. The $18 million transfer from unrealized gain to realized gain, partially
offset by the $2.7 million unrealized gain, resulted in a $15.3 million decrease
to the Partnership's net unrealized appreciation of investments for the three
month period.
For the three months ended March 31, 1995, the Partnership had a $7.4 million
net unrealized gain from its portfolio investments, primarily resulting from the
net upward revaluation of its publicly traded securities. Additionally, during
the three month period, $3.6 million was transferred from unrealized gain to
realized gain related to portfolio investments sold or written-off during the
quarter, as discussed above. The $7.4 million unrealized gain, partially offset
by the $3.6 million transfer from unrealized gain to realized gain, resulted in
a $3.8 million increase to the Partnership's net unrealized appreciation of
investments for the three month period.
Net Assets - Changes to net assets resulting from operations are comprised of 1)
net realized gain or loss from operations and 2) changes to net unrealized
appreciation or depreciation of portfolio investments.
For the three months ended March 31, 1996, the Partnership had a $12.5 million
net increase in net assets resulting from operations, comprised of the $27.8
million net realized gain from operations offset by the $15.3 million decrease
in unrealized appreciation of investments for the three month period. At March
31, 1996, the Partnership's net assets were $71.4 million, down $8.9 million
from $80.3 million at December, 31 1995. This decrease resulted from the $21.4
million accrued cash distribution paid to Partners in April 1996 offset by the
$12.5 million increase in net assets from operations for the three month period.
For the three months ended March 31, 1995, the Partnership had an $11.5 million
net increase in net assets resulting from operations, comprised of the $3.8
million increase in unrealized appreciation of investments and the $7.7 million
net realized gain from operations for the three month period. At March 31, 1995,
the Partnership's net assets were $83.7 million, up $254,000 from $83.4 million
at December 31, 1994. This increase resulted from the $11.5 million net increase
in net assets from operations for the three month period offset by the $11.2
million accrued cash distribution paid to Partners in April 1995.
Gains and losses from investments are allocated to Partners' capital accounts
when realized, in accordance with the Partnership Agreement (see Note 3 of Notes
to Financial Statements). However, for purposes of calculating the net asset
value per unit of limited partnership interest, net unrealized appreciation of
investments has been included as if the net appreciation had been realized and
allocated to the Limited Partners in accordance with the Partnership Agreement.
Pursuant to such calculation, the net asset value per $1,000 Unit at March 31,
1996 and December 31, 1995 was $529 and $596, respectively.
<PAGE>
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
The Partnership has been named as a defendant in an action relating to its
ownership of securities of In-Store Advertising, Inc. ("In-Store Advertising").
On or about July 16, 1993, a Second Amended Consolidated Class Action Complaint
(the "Amended Complaint") was filed in the United States District Court for the
Southern District of New York in the In Re In-Store Advertising Securities
Litigation. The action is a purported class action suit wherein the plaintiffs
(the "Plaintiffs") are persons who allegedly purchased shares of In-Store
Advertising common stock in the July 19, 1990 initial public offering (the
"Offering") and through November 8, 1990. The defendants named in the Amended
Complaint include former individual officers and directors of In-Store
Advertising, the underwriters involved in the Offering, and certain other
defendants, including the Partnership, who owned In-Store Advertising securities
prior to the Offering (the "Venture Capital Defendants"). Prior to the filing of
the Amended Complaint, In-Store Advertising filed a "prepackaged" plan in U.S.
Bankruptcy Court pursuant to Chapter XI of the U.S. Bankruptcy Code. In their
answers to the Amended Complaint, defendants (including the Partnership)
asserted cross-claims for contribution against their then co-defendant KPMG Peat
Marwick (In-Store Advertising's auditors). Plaintiffs' claims against KPMG Peat
Marwick were dismissed as barred by the statute of limitations.
The Amended Complaint alleges violations under Sections 11, 12(2) and 15 of the
Securities Act of 1933, as amended (the "1933 Act"), Section 10(b) and 20 of the
Securities Exchange Act of 1934, as amended (the "1934 Act") and Rule 10b-5
promulgated thereunder, and common law claims of negligent misrepresentation,
fraud and deceit in connection with the sale of securities. The Plaintiffs seek
rescission of the purchases of In-Store Advertising's common stock to the extent
the members of the alleged classes still hold their shares, together with
damages and certain costs and expenses.
The Amended Complaint alleges that the Venture Capital Defendants are liable
under Section 10(b) of the 1934 Act and Rule 10b-5, and are also liable as
controlling persons of In-Store Advertising within the meaning of Section 15 of
the 1933 Act and Section 20(a) of the 1934 Act. The Venture Capital Defendants
are also being sued as alleged knowing and substantial aiders and abettors of
the other defendants' wrongful conduct and under common law fraud and negligence
theories. An individual director of In-Store Advertising, named as a defendant
in the action, was a Vice President of Merrill Lynch Venture Capital Inc., the
General Partner of the Managing General Partner of the Partnership. The
Partnership believes it has meritorious defenses to the allegations in the
Amended Complaint and that the cost of resolution of the litigation will not
have a material impact on the financial condition of the Partnership (see Note 8
of Notes to Financial Statements).
Item 2. Changes in Securities.
Not applicable.
Item 3. Defaults Upon Senior Securities.
Not applicable.
<PAGE>
Item 4. Submission of Matters to a Vote of Security Holders.
No matter was submitted to a vote of security holders during the period in which
this report covers.
Item 5. Other Information.
In January 1996, the Partnership purchased 36,882 shares of preferred stock of
Neocrin Company and a warrant to purchase 922,050 shares of Neocrin preferred
stock at $.40 per share for $184,502.
Also in January 1996, the Partnership paid $22,609 to MLMS Cancer Research, Inc.
in connection with a call on the non-interest bearing promissory note payable on
demand to MLMS. The payment increased the cost basis of the Partnership's common
stock investment in the company from $46,957 to $69,566 and reduced the
outstanding obligation under the promissory note from $393,043 to $370,434.
<PAGE>
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
<TABLE>
<S> <C> <C> <C>
(3) (a) Amended and Restated Certificate of Limited Partnership of the Partnership, dated as of January
12, 1987. (1)
(3) (b) Amended and Restated Certificate of Limited
Partnership of the Partnership, dated July 27, 1990.
(2)
(3) (c) Amended and Restated Certificate of Limited Partnership of the Partnership, dated March 25,
1991. (3)
(3) (d) Amended and Restated Agreement of Limited Partnership of the Partnership, dated as of May 4,
1987. (4)
(3) (e) Amendment No. 1 dated February 14, 1989 to Amended and Restated Agreement of Limited Partnership
of the Partnership. (5)
(3) (f) Amendment No. 2 dated July 27, 1990 to Amended and Restated Agreement of Limited Partnership of
the Partnership. (2)
(3) (g) Amendment No. 3 dated March 25, 1991 to Amended and Restated Agreement of Limited Partnership of
the Partnership. (3)
(3) (h) Amendment No. 4 dated May 23, 1991 to Amended and Restated Agreement of Limited Partnership of
the Partnership. (6)
(10) (a) Management Agreement dated as of May 23, 1991 among the Partnership, Management Company and the
Managing General Partner. (6)
(10) (b) Sub-Management Agreement dated as of May 23, 1991 among the Partnership, Management Company, the
Managing General Partner and the Sub-Manager. (8)
(27) Financial Data Schedule.
(28) Prospectus of the Partnership dated February 10,
1987 filed with the Securities and Exchange
Commission pursuant to Rule 424(b) under the
Securities Act of 1933, as supplemented by a
supplement thereto dated April 21, 1987 filed
pursuant to Rule 424(c) under the Securities Act
of 1933. (7)
(b) No reports on Form 8-K have been filed during the quarter for which this report is filed.
</TABLE>
<PAGE>
(1) Incorporated by reference to the Partnership's Annual Report on Form 10-K
for the year ended December 31, 1988 filed with the Securities and Exchange
Commission on March 27, 1989.
(2) Incorporated by reference to the Partnership's Quarterly Report on Form
10-Q for the quarter ended September 30, 1990 filed with the Securities and
Exchange Commission on November 14, 1990.
(3) Incorporated by reference to the Partnership's Annual Report on Form 10-K
for the year ended December 31, 1990 filed with the Securities and Exchange
Commission on March 28, 1991.
(4) Incorporated by reference to the Partnership's Quarterly Report on Form
10-Q for the quarter ended June 30, 1987 filed with the Securities and
Exchange Commission on August 14, 1987.
(5) Incorporated by reference to the Partnership's Quarterly Report on Form
10-Q for the quarter ended March 31, 1989 filed with the Securities and
Exchange Commission on May 15, 1989.
(6) Incorporated by reference to the Partnership's Quarterly Report on Form
10-Q for the quarter ended June 30, 1991 filed with the Securities and
Exchange Commission on August 14, 1991.
(7) Incorporated by reference to the Partnership's Quarterly Report on Form
10-Q for the quarter ended March 31, 1987 filed with the Securities and
Exchange Commission on May 15, 1987.
(8) Incorporated by reference to the Partnership's Annual Report on Form 10-K
for the year ended December 31, 1992 filed with the Securities and Exchange
Commission on March 26, 1993.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ML VENTURE PARTNERS II, L.P.
By: /s/ Kevin K. Albert
Kevin K. Albert
General Partner
By: MLVPII Co., L.P.
its Managing General Partner
By: Merrill Lynch Venture Capital Inc.
its General Partner
By: /s/ Kevin K. Albert
Kevin K. Albert
President
(Principal Executive Officer)
By: /s/ Diane T. Herte
Diane T. Herte
Vice President and Treasurer
(Principal Financial and Accounting Officer)
Date: May 14, 1996
<TABLE> <S> <C>
<ARTICLE> 6
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM ML VENTURE
PARTNERS II, L.P.'S QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED MARCH 31,
1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-1-1996
<PERIOD-END> MAR-31-1996
<INVESTMENTS-AT-COST> 68,439,066
<INVESTMENTS-AT-VALUE> 88,395,020
<RECEIVABLES> 4,788,400
<ASSETS-OTHER> 0
<OTHER-ITEMS-ASSETS> 69,058
<TOTAL-ASSETS> 93,252,478
<PAYABLE-FOR-SECURITIES> 0
<SENIOR-LONG-TERM-DEBT> 0
<OTHER-ITEMS-LIABILITIES> 21,795,939
<TOTAL-LIABILITIES> 21,795,939
<SENIOR-EQUITY> 0
<PAID-IN-CAPITAL-COMMON> 0
<SHARES-COMMON-STOCK> 120,000
<SHARES-COMMON-PRIOR> 120,000
<ACCUMULATED-NII-CURRENT> 0
<OVERDISTRIBUTION-NII> 0
<ACCUMULATED-NET-GAINS> 0
<OVERDISTRIBUTION-GAINS> 0
<ACCUM-APPREC-OR-DEPREC> 19,814,006
<NET-ASSETS> 71,456,539
<DIVIDEND-INCOME> 66,700
<INTEREST-INCOME> 292,041
<OTHER-INCOME> 0
<EXPENSES-NET> 379,909
<NET-INVESTMENT-INCOME> (21,168)
<REALIZED-GAINS-CURRENT> 27,824,851
<APPREC-INCREASE-CURRENT> (15,311,178)
<NET-CHANGE-FROM-OPS> 12,492,505
<EQUALIZATION> 0
<DISTRIBUTIONS-OF-INCOME> 0
<DISTRIBUTIONS-OF-GAINS> 0
<DISTRIBUTIONS-OTHER> 21,378,498
<NUMBER-OF-SHARES-SOLD> 0
<NUMBER-OF-SHARES-REDEEMED> 0
<SHARES-REINVESTED> 0
<NET-CHANGE-IN-ASSETS> (1,792,931)
<ACCUMULATED-NII-PRIOR> 0
<ACCUMULATED-GAINS-PRIOR> 0
<OVERDISTRIB-NII-PRIOR> 0
<OVERDIST-NET-GAINS-PRIOR> 0
<GROSS-ADVISORY-FEES> 0
<INTEREST-EXPENSE> 0
<GROSS-EXPENSE> 0
<AVERAGE-NET-ASSETS> 75,899,536
<PER-SHARE-NAV-BEGIN> 596
<PER-SHARE-NII> 0
<PER-SHARE-GAIN-APPREC> 83
<PER-SHARE-DIVIDEND> 0
<PER-SHARE-DISTRIBUTIONS> (150)
<RETURNS-OF-CAPITAL> 0
<PER-SHARE-NAV-END> 529
<EXPENSE-RATIO> 0
<AVG-DEBT-OUTSTANDING> 0
<AVG-DEBT-PER-SHARE> 0
</TABLE>
